RxDoctor Payments Data

Todd Rexford, MD

Family Medicine · Norton Shores, MINPI 1740284330

Payments from drug & device makers

$686in general payments, 2019–2025

Across 27 payments — averaging $25.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$157
  • Life Molecular Imaging Ltd$135
  • Pfizer$52
  • Novo Nordisk$47
  • Amgen$43
  • Novartis$42
  • plus $210 from 11 others

What the payments were for

  • Food & beverage$686100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$686 in reported general payments places this provider in the 65th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$51,930
Medicare patients
60
Services billed
675

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$103,757
Tresiba Flextouch U-200Insulin Degludec26$20,991
OzempicSemaglutide19$17,517
FarxigaDapagliflozin Propanediol12$15,366
EntrestoSacubitril/Valsartan16$14,093
MyrbetriqMirabegron17$14,041
MounjaroTirzepatide11$11,045
InvokanaCanagliflozin14$7,881
Omeprazole102$2,354
Rosuvastatin Calcium79$2,285
Atorvastatin Calcium113$2,122
Tamsulosin Hcl81$1,661
Diltiazem 24hr Er (Cd)Diltiazem Hcl19$1,537
Potassium Chloride23$1,416
Lisinopril127$1,399

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$52$103,75779 claims
Novo NordiskOzempic$47$17,51719 claims
AstraZenecaFarxiga$12$15,36612 claims
NovartisEntresto$42$14,09316 claims
Astellas Pharma US IncMyrbetriq$20$14,04117 claims
Lilly USA, LLCMounjaro$14$11,04511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Norton Shores

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →